Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Autonomic and Immune Effects of Regional Anesthesia in Total Hip Arthroplasty (PENG neuromodu)

3. november 2026 opdateret af: Poznan University of Medical Sciences

Effects of Three Regional Anesthesia Strategies on Autonomic Regulation, Systemic Inflammatory Response, and Postoperative Recovery Following Elective Total Hip Arthroplasty: A Prospective Randomized Double-Blind Trial

Surgical trauma activates the sympathetic nervous system and induces a systemic inflammatory response, both of which may adversely affect postoperative recovery. Regional anesthesia has traditionally been used for perioperative analgesia; however, emerging evidence suggests that peripheral nerve blocks may also modulate autonomic and immune pathways. This prospective randomized double-blind trial aims to compare three regional anesthesia strategies in patients undergoing elective total hip arthroplasty under spinal anesthesia and to determine their effects on autonomic regulation, systemic inflammatory response, postoperative pain, opioid consumption, quality of recovery, and early functional outcomes.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Total hip arthroplasty (THA) is associated with substantial surgical trauma, resulting in activation of the sympathetic nervous system and a systemic inflammatory response that may contribute to postoperative pain, delayed functional recovery, and perioperative complications. Although regional anesthesia techniques are widely used to improve postoperative analgesia, increasing evidence suggests that they may also influence autonomic regulation and neuroimmune interactions beyond their analgesic effects. The extent to which different regional anesthesia strategies modify perioperative autonomic and inflammatory responses remains incompletely understood.

This prospective, randomized, double-blind, controlled trial aims to compare three regional analgesic strategies in patients undergoing elective primary total hip arthroplasty under spinal anesthesia: ultrasound-guided pericapsular nerve group (PENG) block, local infiltration analgesia (LIA), and the combination of PENG block with LIA. All patients will receive standardized perioperative anesthetic and multimodal analgesic management, with the regional analgesic technique being the only study intervention.

The primary objective is to determine whether different regional anesthesia strategies differentially influence perioperative autonomic regulation and systemic inflammatory response. Autonomic function will be assessed using perioperative hemodynamic parameters and vasopressor requirements, while systemic inflammatory activation will be evaluated using routinely available inflammatory biomarkers, including the Systemic Immune-Inflammation Index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), and other laboratory markers measured before and after surgery.

Secondary objectives include comparison of postoperative pain intensity at rest and during movement, opioid consumption, time to first rescue analgesia, quality of recovery assessed using the Quality of Recovery-15 (QoR-15) questionnaire, incidence of postoperative nausea and vomiting, time to first ambulation, length of hospital stay, patient satisfaction, and the incidence of postoperative complications.

The study is designed to determine whether combining peripheral nerve blockade with periarticular infiltration provides additive benefits not only for postoperative analgesia but also for modulation of autonomic-immune interactions and enhancement of postoperative recovery. The findings may improve understanding of peripheral nerve blocks as a form of perioperative neuromodulation and support optimization of regional anesthesia strategies in patients undergoing total hip arthroplasty.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

165

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Poznan, Polen, 62-701
        • Poznan University of Medical Sciences

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 100 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged ≥18 years.
  • Scheduled for elective primary total hip arthroplasty due to primary hip osteoarthritis.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Planned spinal anesthesia with one of the study regional analgesia techniques.
  • Ability to understand the study procedures and provide written informed consent.

Exclusion Criteria:

  • Refusal or inability to provide written informed consent.
  • Revision hip arthroplasty, simultaneous bilateral hip arthroplasty, or hip arthroplasty performed for an acute fracture.
  • Known hypersensitivity to ropivacaine or other medications required for the study procedures.
  • Contraindication to spinal anesthesia, PENG block, or local infiltration analgesia, including infection at the injection site or a coagulation disorder or antithrombotic treatment that precludes safe performance of the planned procedures.
  • Pre-existing neurological or neuromuscular disease that substantially affects sensation or motor function in the operated limb or prevents reliable assessment of study outcomes.
  • Cognitive impairment or a communication disorder that prevents understanding of the study procedures or reliable completion of pain assessments.
  • A medical condition that, in the investigator's judgment, makes participation or the planned anesthetic procedures unsafe.
  • Planned use of an additional regional analgesic technique outside the study protocol.
  • Participation in another interventional study that could interfere with the assessment of the study outcomes.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: PENG Block

Ropivacaine for Pericapsular Nerve Group (PENG) Block

Ultrasound-guided single-injection pericapsular nerve group (PENG) block performed before surgery using 20ml of 0.2% ropivacaine

Andre navne:
  • PENG
  • Perikapsulær nervegruppeblok
  • 0.2% Ropimol
Eksperimentel: Local Infiltration Analgesia (LIA)

Ropivacaine for Local Infiltration Analgesia

Local infiltration analgesia is performed intraoperatively - 20ml 0.2% ropivacaine

Andre navne:
  • Periarticular Infiltration Analgesia
  • 0.2% ropimol
Eksperimentel: Combined PENG Block + LIA

Ropivacaine for Pericapsular Nerve Group (PENG) block before surgery and Local Infiltration Analgesia (LIA)

Ultrasound-guided single-injection pericapsular nerve group (PENG) block performed before surgery using 20ml of 0.2% ropivacaine

Andre navne:
  • PENG
  • Perikapsulær nervegruppeblok
  • 0.2% Ropimol

Local infiltration analgesia is performed intraoperatively - 20ml 0.2% ropivacaine

Andre navne:
  • Periarticular Infiltration Analgesia
  • 0.2% ropimol

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Systemic Immune-Inflammation Index (SII)
Tidsramme: 24 hours after surgery

Comparison of the change in Systemic Immune-Inflammation Index from baseline to postoperative 24 hours among the three study groups.

24 hours after surgery

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Neutrophil-to-Lymphocyte Ratio (NLR)
Tidsramme: 24 hours after surgery

Comparison of the change in neutrophil-to-lymphocyte ratio among the three study groups.

24 hours after surgery
Neutrophil-to-Lymphocyte Ratio (NLR)
Tidsramme: 12 hours after surgery

Comparison of the change in neutrophil-to-lymphocyte ratio among the three study groups.

12 hours after surgery
Neutrophil-to-Lymphocyte Ratio (NLR)
Tidsramme: 48 hours after surgery

Comparison of the change in neutrophil-to-lymphocyte ratio among the three study groups.

48 hours after surgery
Platelet-to-Lymphocyte Ratio (PLR)
Tidsramme: 24 hours after surgery

Comparison of the change in platelet-to-lymphocyte ratio among the three study groups.

24 hours after surgery
Platelet-to-Lymphocyte Ratio (PLR)
Tidsramme: 48 hours after surgery

Comparison of the change in platelet-to-lymphocyte ratio among the three study groups.

48 hours after surgery
Platelet-to-Lymphocyte Ratio (PLR)
Tidsramme: 12 hours after surgery

Comparison of the change in platelet-to-lymphocyte ratio among the three study groups.

12 hours after surgery
Postoperative pain intensity
Tidsramme: 2 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

2 hours after surgery
Postoperative pain intensity at movement
Tidsramme: 2 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

2 hours after surgery
Postoperative pain intensity at movement
Tidsramme: 6 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

6 hours after surgery
Postoperative pain intensity at movement
Tidsramme: 12 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

12 hours after surgery
Postoperative pain intensity at movement
Tidsramme: 24 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

24 hours after surgery
Postoperative pain intensity at movement
Tidsramme: 48 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

48 hours after surgery
Postoperative pain intensity
Tidsramme: 6 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

6 hours after surgery
Postoperative pain intensity
Tidsramme: 12 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

12 hours after surgery
Postoperative pain intensity
Tidsramme: 24 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

24 hours after surgery
Postoperative pain intensity
Tidsramme: 48 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

48 hours after surgery
Postoperative opioid consumption
Tidsramme: 48 hours after surgery

Comparison of cumulative opioid consumption during the postoperative period, expressed as intravenous morphine milligram equivalents (MME).

48 hours after surgery
Time to first rescue analgesia
Tidsramme: 48 hours after surgery

Comparison of the time from the end of surgery to the first administration of rescue opioid analgesia.

48 hours after surgery
Systemic Immune-Inflammation Index (SII)
Tidsramme: 24 hours after surgery

Comparison of the change in the Systemic Immune-Inflammation Index (SII) among the three study groups.

24 hours after surgery
Systemic Immune-Inflammation Index (SII)
Tidsramme: 12 hours after surgery

Comparison of the change in the Systemic Immune-Inflammation Index (SII) among the three study groups.

12 hours after surgery
Systemic Immune-Inflammation Index (SII)
Tidsramme: 48 hours after surgery

Comparison of the change in the Systemic Immune-Inflammation Index (SII) among the three study groups.

48 hours after surgery
C-reactive protein (CRP)
Tidsramme: 12 hours after surgery

Comparison of postoperative C-reactive protein (CRP) concentrations among the three study groups.

12 hours after surgery
C-reactive protein (CRP)
Tidsramme: 24 hours after surgery

Comparison of postoperative C-reactive protein (CRP) concentrations among the three study groups.

24 hours after surgery
C-reactive protein (CRP)
Tidsramme: 48 hours after surgery

Comparison of postoperative C-reactive protein (CRP) concentrations among the three study groups.

48 hours after surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

30. december 2027

Studieafslutning (Anslået)

1. januar 2028

Datoer for studieregistrering

Først indsendt

29. juli 2026

Først indsendt, der opfyldte QC-kriterier

3. november 2026

Først opslået (Faktiske)

9. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 18/2026

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data underlying the published results will be made available upon reasonable request to the corresponding author. Data will be shared after publication of the primary study results and following approval of a methodologically sound research proposal and completion of a data sharing agreement.

IPD-delingstidsramme

Data will be available beginning 6 months after publication of the primary results and for a period of 5 years.

IPD-delingsadgangskriterier

Researchers who provide a methodologically sound proposal aimed at achieving the objectives of the approved proposal will be granted access. Requests should be directed to the corresponding author. A data access agreement will be required prior to data release.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner